We are live on
!
Find out more
LOAMS
Lombard Odier Asset Management (Switzerland) Portfolio holdings
AUM
$2.63B
1-Year Est. Return
31.52%
This Fund
S&P 500
This Quarter
Est. Return
-6.61%
1 Year Est. Return
+31.52%
3 Year Est. Return
+98.77%
5 Year Est. Return
+107.98%
10 Year Est. Return
+494.97%
AUM
$1.27B
AUM Growth
-$291M
(-19%)
Cap. Flow
-$139M
Cap. Flow
% of AUM
-10.93%
Top 10 Holdings %
Top 10 Hldgs %
24.84%
Holding
415
New
40
Increased
54
Reduced
57
Closed
258
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$34.3M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$24.4M |
| 3 |
Incyte
INCY
|
+$24.2M |
| 4 |
Equity Lifestyle Properties
ELS
|
+$23.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$22.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pultegroup
PHM
|
+$28.6M |
| 2 |
Biogen
BIIB
|
+$24.6M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$24.1M |
| 4 |
Abbott
ABT
|
+$16.3M |
| 5 |
Pool Corp
POOL
|
+$14.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 56.62% |
| 2 | Financials | 13.8% |
| 3 | Consumer Discretionary | 12.01% |
| 4 | Technology | 6.24% |
| 5 | Energy | 3.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
AbbVie
ABBV
$442B
| $34.4M | 2.7% |
211,960
-25,524
| -11% | -$3.71M |
|
|
2
CVS Health
CVS
$119B
| $34.1M | 2.67% |
336,467
+326,473
| +3,267% | +$34.3M |
|
3
Thermo Fisher Scientific
TMO
$223B
| $34M | 2.67% |
57,591
-101
| -0.2% | -$58K |
|
|
LHCG
4
DELISTED
LHC Group LLC
LHCG
| $33.7M | 2.64% |
200,000
| – | – |
|
5
UnitedHealth
UNH
$366B
| $33.6M | 2.64% |
65,956
-15,167
| -19% | -$7.32M |
|
6
IQVIA
IQV
$40.3B
| $32.3M | 2.53% |
139,563
+6,674
| +5% | +$1.58M |
|
7
Medifast
MED
$131M
| $29.9M | 2.34% |
175,000
| – | – |
|
8
Service Corp International
SCI
$11.4B
| $29.6M | 2.32% |
450,000
| – | – |
|
|
CIXX
9
DELISTED
CI Financial Corp.
CIXX
| $27.8M | 2.18% |
1,750,000
+250,000
| +17% | +$4.46M |
|
10
Ameriprise Financial
AMP
$49.8B
| $27.3M | 2.14% |
90,978
-10,304
| -10% | -$3.12M |
|
11
Visa
V
$678B
| $27.2M | 2.14% |
122,862
+6,891
| +6% | +$1.49M |
|
|
HOLX
12
DELISTED
Hologic
HOLX
| $26.4M | 2.07% |
343,825
+17,391
| +5% | +$1.25M |
|
|
13
Incyte
INCY
$24.5B
| $26.4M | 2.07% |
+332,498
| New | +$24.2M |
|
|
14
Bristol-Myers Squibb
BMY
$130B
| $26.2M | 2.05% |
358,298
+337,756
| +1,644% | +$22.7M |
|
15
Brunswick
BC
$5.29B
| $25.1M | 1.97% |
310,037
+10,037
| +3% | +$926K |
|
16
American Express
AXP
$231B
| $25M | 1.96% |
133,557
-41,246
| -24% | -$7.45M |
|
17
Halozyme
HALO
$11.8B
| $24.5M | 1.92% |
+614,090
| New | +$21.9M |
|
18
Labcorp
LH
$26.1B
| $23.9M | 1.88% |
105,593
-578
| -0.5% | -$136K |
|
19
GoodRx Holdings
GDRX
$1.31B
| $23.1M | 1.81% |
1,193,122
+275,849
| +30% | +$6.33M |
|
|
20
Equity Lifestyle Properties
ELS
$12.5B
| $22.9M | 1.8% |
+300,000
| New | +$23.2M |
|
|
21
BioMarin Pharmaceuticals
BMRN
$13.4B
| $22.5M | 1.77% |
+291,870
| New | +$24.4M |
|
|
SCHW
22
Charles Schwab
SCHW
$186B
| $21.8M | 1.71% |
258,629
-49,943
| -16% | -$4.39M |
|
23
Tandem Diabetes Care
TNDM
$1.65B
| $21.7M | 1.7% |
186,756
-6,405
| -3% | -$748K |
|
24
Thor Industries
THO
$4.23B
| $21.6M | 1.7% |
275,000
+25,000
| +10% | +$2.3M |
|
25
Lowe's Companies
LOW
$124B
| $21.1M | 1.65% |
104,316
-1,236
| -1% | -$284K |
|
Similar funds
SI
WWM
ACM
CCM
MG
PCMI
PCIG
MAMU
Lombard Odier Asset Management (Switzerland)'s Q1 2022 Portfolio in Review
As of Q1 2022, Lombard Odier Asset Management (Switzerland) held 415 positions worth $1.27B, down 19% from $1.57B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Lombard Odier Asset Management (Switzerland) withdrew a net $139M in Q1 2022, closing 258 positions and reducing 57 holdings. Its most notable exit was Pultegroup, an estimated $28.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 53% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Lombard Odier Asset Management (Switzerland) opened a new position in BioMarin Pharmaceuticals worth $22.5M.
- Lombard Odier Asset Management (Switzerland)'s largest Q1 2022 buy was BioMarin Pharmaceuticals: 291,870 shares worth $22.5M.
- Lombard Odier Asset Management (Switzerland) added most to CVS Health in Q1 2022, an estimated $34.3M increase.
- Lombard Odier Asset Management (Switzerland)'s biggest Q1 2022 reduction was Abbott, cutting an estimated $16.3M.
- Lombard Odier Asset Management (Switzerland) fully exited Pultegroup in Q1 2022, selling an estimated $28.6M.
- Lombard Odier Asset Management (Switzerland)'s ten largest holdings make up 25% of its $1.27B portfolio in Q1 2022.
- Lombard Odier Asset Management (Switzerland) opened 40 new positions and closed 258 in Q1 2022.
- Lombard Odier Asset Management (Switzerland)'s portfolio value fell 19% quarter-over-quarter to $1.27B.
Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q1 2022, filed 16 May 2022.